Weather Forecast for Saturday    Tunisian Foreign Minister Meets with His Algerian Counterpart    Wall Street Closing    Semi-automated offside technology approved by FIFA for 2022 World Cup    Airport workers strike ground some flights in Paris    Deputy Foreign Minister Participates in Burundi's Celebration of 60th Independence Day    Over 344,000 Hajj pilgrims arrive in Madinah    Jordanian minister all praise for transport services offered to Hajj pilgrims    Hajj Ministry releases awareness guides in 14 languages    KSrelief Distributes 6,000 Cartons of Dates in Lahij Governorate, Yemen    GCC Secretary-General Praises Saudi Arabia's New Development Projects in Yemen    ETEC Obtains Membership of Washington Accord for Engineering Programs    CITC Publishes a Public Consultation on the Spectrum Use Regulation for Amateur Radio Services    Saudia Celebrates Launch of Seasonal Route From Riyadh to Mykonos    Saudi National Basketball Team Beats Indonesia in World Cup Qualifiers    KSA's Representative and Head of Donor Group to Support UN OCHA Participates in High-level Meeting of Donors in The Hague    EU agrees on landmark crypto regulation in wake of Terra meltdown, Bitcoin plunge    Ukraine war: '18 dead' as Russian missiles hit residential areas in Odesa    FBI adds missing Cryptoqueen to top ten most wanted    Saudi ministry updates rules allowing house workers to switch jobs without employer consent    Xi Jinping defends Chinese rule at Hong Kong handover anniversary    Saudi Arabia issues 80 mining licenses in May    Health and wellness on top of Saudi national priorities for research and development    Top retail professionals of the region honored at RetailME Summit    Saudi-French Coordination to Increase French Mining Investments in Saudi Arabia    Heritage Commission Signs Agreement with to Support Saudi Sellers, Local Crafts Sector    Five era-defining artworks commissioned for iconic new cultural destination 'Wadi AlFann'    Red Sea Fund Opens Its Third Cycle for Production Funding    SFDA warns against herbal product 'Montalin Jamu' due to containing active medicinal ingredients    SFDA Warns Against Herbal Product "Montalin Jamu" Due to Containing Active Medicinal Ingredients    Al-Hilal lifts MBS League title for 3rd time in a row, beating Al-Faisaly    Al-Ahli relegated for first time in history    Ithra expands 'iRead' competition to participants from all Arab countries    NEOM, McLaren Racing announce strategic title partnership to drive innovation in electric motorsport    Morocco and Iraq to the finals of Arab Futsal in Dammam on Tuesday    Saudi US Joint Exhibition on Photography Concludes in Tabuk    Venice-based art exhibition sheds light on upcoming Saudi talents    Makkah Municipality offers animal sacrifices permitting service through Baladi platform    First Saudi-American Joint Exhibition of Photography held in Tabuk Region    FIFA Accredits Saudi Football Association Among Expert Federations in VAR Tech    Jeddah is Set to Host the Finals of World Boxing in August, Organizers Announce    Samrat Prithviraj: Why did a Bollywood film on a popular Hindu king fail?    Saudi Council of Senior Scholars slams Indian ruling party leader's remarks against Prophet    Drug charges dropped against Shah Rukh Khan's son    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Study: Oxford COVID-19 vaccine is safe and triggers response in adults over 56
Published in The Saudi Gazette on 19 - 11 - 2020

Phase 2 trials of Oxford University's COVID-19 vaccine in healthy older adults have found it is safe and provokes an immune response.
The university confirmed that the candidate vaccine it is developing with AstraZeneca showed similar safety and immunogenicity results in healthy older people (aged 56 and over) to those seen in adults aged 18-55 years.
Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.
The early-stage results, which they described as "promising" were published Thursday in The Lancet medical journal.
The phase 2 trial, which involved 560 adults including 240 over the age of 70, found that the vaccine causes few side effects and induces immune responses in both parts of the immune system in all age groups.
Results showed within 14 days of the first dose of vaccination it provoked a T cell response — it could find and attack cells infected with the virus — and caused an antibody response within 28 days of the booster jab.
Phase 3 trials, which involve thousands of participants, are ongoing to confirm these results, as well as how effective the vaccine is in protecting against infection with SARS-CoV-2 (the strain of the virus that causes coronavirus disease) in a broader range of people, including older adults with underlying health conditions, according to the vaccine's developers
"Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections," said study lead author, Professor Andrew Pollard from the University of Oxford.
"As a result, it is crucial that COVID-19 vaccines are tested in this group who are also a priority group for immunization."
Late-stage trial results will show if the Astra-Oxford vaccine can meet the standard set by front-runners Pfizer-BioNTech and Moderna.
Pfizer and BioNTech said Wednesday that the coronavirus vaccine they were developing has been proved 95 percent effective overall, with efficacy in adults over 65 years of age at 94 percent.
The US and German pharmaceuticals organizations said the candidate now met the safety criteria needed for emergency authorization.
US biotechnology company Moderna said on Monday that, based on preliminary data, their potential coronavirus vaccine has been deemed to be 94.5 percent effective at preventing people from getting the virus.
Trials for the Astra-Oxford vaccine candidate were paused in September after a participant fell ill.
They were restarted again after the company had investigated whether a vaccine recipient's "potentially unexplained" illness was a result of receiving the jab.
In large trials like this one, "it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety," the Oxford University said.
It did not disclose medical information about the illness that caused the trial to be put on hold, citing participant confidentiality.
Health experts, including the UK government's chief scientific adviser, Sir Patrick Vallance, have said pauses in drug trials are commonplace to ensure safety and effectiveness. — Courtesy Euro mews

Clic here to read the story from its source.